Navigation Links
Masimo to Present at Deutsche Bank 33rd Annual Health Care Conference
Date:5/1/2008

IRVINE, Calif., May 1 /PRNewswire-FirstCall/ -- Masimo Corporation (Nasdaq: MASI), the inventor of Pulse CO-Oximetry-and-Measure-Through-Motion- and-Low-Perfusion pulse oximetry, today announced that it is scheduled to present at the Deutsche Bank 33rd Annual Health Care Conference at the InterContinental Boston in Boston, MA on Tuesday, May 6, 2008 at 9:30 a.m. ET. Joe E. Kiani, Chairman will be presenting.

A live Web cast of the presentation will be available on the Masimo Web site at http://www.masimo.com. A replay of the Web cast will be available following the live presentation.

About Masimo

Masimo (Nasdaq: MASI) develops innovative monitoring technologies that significantly improve patient care -- helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through-Motion-and-Low-Perfusion pulse oximetry, known as Masimo SET, and with it virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies demonstrate Masimo SET provides the most trustworthy SpO2 and pulse rate measurements even under the most difficult clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET, a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Rainbow SET continuously and noninvasively measures tota
'/>"/>

SOURCE Masimo Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
2. Masimo Reports Second Quarter 2007 Financial Results
3. Masimo Launches Patient SafetyNet and Showcases the Rainbow SET Upgradable Noninvasive Monitoring Platform at 2007 ASA Annual Meeting
4. Masimo to Report Third Quarter 2007 Financial Results on October 30, 2007
5. Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan
6. Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
7. Masimo Awarded Multi-Year Pulse Oximetry Agreement with HealthTrust Purchasing Group
8. Masimo Announces Continuous Noninvasive Total Hemoglobin
9. Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results
10. Masimo to Present at Citi Investment Research 5th Annual Small & Mid-Cap Conference
11. Schiller AG Adopts Masimo Rainbow SET as Their Technology Platform of Choice for Patient Monitoring Devices Worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Los Angeles, CA (PRWEB) June 18, 2013 (PRWEB) ... of construction’s #1 time and attendance system in ... transfer software that shares employee data and payroll ... , AccountLinx Plus automates ExakTime software ... applications. The software imports employee data from a ...
(Date:6/18/2013)... 2013 Nasseo, Inc. today announces that ... out of hundreds of applicants by the Arizona ... Innovation Challenge . The Arizona Innovation Challenge (AIC) awards ... commercialization challenge, granting a financial award to what it ... Nasseo’s state of the art dental and orthopedic implant ...
(Date:6/18/2013)... 2013  AMRI (NASDAQ: AMRI ) ... , site has received approval to expand ... to handle Schedule 2 and 2N controlled substances. ... Burlington,s physical security and quality ... (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) With ...
(Date:6/18/2013)... June 18, 2013 ... announced the addition of the report " ... " to their offering.      ... reviews basics of human genome variations, development ... large and small sequencers are described as ...
Breaking Biology Technology:ExakTime Introduces AccountLinx Plus 2Nasseo Named 2013 Innovation Challenge Winner by Arizona Commerce Authority 2AMRI Burlington Receives DEA Approval to Handle Controlled Substances 2DNA Sequencing: Technologies, Markets and Companies - 2013 Report 2
... -. Actavis Group, the,international generic pharmaceuticals company, has ... Food & Drug,Administration. Distribution of the product will ... equivalent to Pfizer,s,Camptosar(R) will be available in 40 ... and is,used in the treatment of patients with ...
... CryoCath,s Cryoablation System, SAN DIEGO, Feb. 28 ... focused on the treatment of cardiac,arrhythmias, announced today ... the,United States International Trade Commission (ITC) alleging that ... by infringing on,several CryoCor patents with its cryoablation ...
... Johnson, Jr. Resigns as President and Chief Executive ... Opportunities, HAYWARD, Calif., Feb. 28 Kosan ... Robert G. Johnson, Jr.,M.D., Ph.D., has resigned as ... Kosan,s Board of Directors. Helen S. Kim, who ...
Cached Biology Technology:Actavis Receives Approval for Irinotecan Hydrochloride Injection; Extends US Portfolio with First Injectable Product 2CryoCor Requests International Trade Commission Investigation Into CryoCath for Patent Infringement 2CryoCor Requests International Trade Commission Investigation Into CryoCath for Patent Infringement 3Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 2Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 3Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 4Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 5Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 6Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 7Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 8
(Date:6/18/2013)... Department,s National Renewable Energy Laboratory (NREL), and the ... describing a novel cellulose-degrading enzyme from a marine ... as the gribble. , Gribbles are biologically ... to produce their own enzymes instead of using ... eat. New biomass-degrading enzymes from novel sources such ...
(Date:6/18/2013)... The National Institutes of Health has awarded $12.7 ... a selection of pharmaceutical industry compounds to explore ... including Alzheimer,s disease, Duchenne muscular dystrophy and schizophrenia. ... Uses for Existing Molecules, is led by the ... funded by the NIH Common Fund. , The ...
(Date:6/18/2013)... chemical modification of DNA and this modification can ... sequence. Until now, scientists believed that this epigenetic ... Today, a team of researchers from the University ... Louis-Jeantet Professor at the Faculty of Medicine, reveals ... that DNA methylation may play both a passive ...
Breaking Biology News(10 mins):Novel enzyme from tiny gribble could prove a boon for biofuels research 2NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4The secret of DNA methylation 2
... us to spot prey, vision keeps many animals, including humans, ... why is it easier for us to spot movement of ... other things? The complexity of the neural network that supports ... technology and support from the National Science Foundation, Claire Wyart ...
... Calif., November 1, 2010 One of the many advantages ... which in turn supports a healthy heart. Fat tissue is ... it,s also an active secretory organ that normally produces high ... the hearts of healthy people has long been a mystery, ...
... developing a cost-effective electronic monitoring system that will enable ... by allowing users to track water-quality data from these ... National Science Foundation (NSF) grant. "Our goal is ... conditions in the Chesapeake Bay, the sounds of North ...
Cached Biology News:The zebrafish's neural circuit prevents it from biting off more than it can chew 2Study finds fat hormone's long-sought link to heart protection 2Researchers developing real-time electronic monitoring for coastal waters 2
...
... Solid phase reagent ... purification; Easy & unique ... Compatible with detergents and ... & recover non-envelop viruses ...
Synaptic Vesicle I Sampler Kit 10g each...
Mouse monoclonal [3A7.A11] to Thymidylate Synthase ( Abpromise for all tested applications). entrezGeneID: 7298 SwissProtID: P04818...
Biology Products: